Skip to main content

Alternative Credit News, Hedge Fund News, Private Equity News

DWS Holds Final Close On Maiden Mid-Life Secondaries Private Equity Solutions Fund

DWS has held the final close of its inaugural Private Equity Solutions (PES) fund. PES received $550mn including discretionary co-investment vehicles, which is in excess of its target and hard-cap of $500mn and $525mn respectively.

The private equity business at DWS has focused on developing a differentiated mid-life secondaries strategy that offers a compelling risk-return profile to investors whilst allowing existing private equity sponsors to continue to back their better performing portfolio companies. The strategy provides acquisition / M&A capital to existing portfolio companies, delivering partial liquidity solutions on single assets or structuring continuation fund solutions for GPs and their investors.

In a joint statement, Kumber Husain, Head of Private Equity Americas, and Daniel Green, Head of Private Equity EMEA at DWS, said: “We are proud to have attracted such a high-quality investor base to our mid-life secondaries strategy, which offers an appealing solution to private equity sponsors to continue growing their better performing assets. The strong portfolio of investments we have developed to date has contributed to demand from investors against the backdrop of the on-going growth in GP-led secondaries and bespoke capital solutions.”

Mark McDonald, Global Head of Private Equity at DWS added, “It is a testament to the strength of our team globally for the inaugural PES fund to be oversubscribed, and with the majority of the fundraise taking place during the current Covid pandemic. We seek to deliver consistent risk-adjusted returns to our investors as we continue to build out our team and extend our reach going forward”.

Content role
Free

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.